Raloxifene: a selective estrogen receptor modulator.

Article Details

Citation

Copy to clipboard

Scott JA, Da Camara CC, Early JE

Raloxifene: a selective estrogen receptor modulator.

Am Fam Physician. 1999 Sep 15;60(4):1131-9.

PubMed ID

10507743 [ View in PubMed

]

Abstract

Raloxifene is a selective estrogen receptor modulator that produces both estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue. Because of its tissue selectivity, raloxifene may have fewer side effects than are typically observed with estrogen therapy. The most common adverse effects of raloxifene are hot flushes and leg cramps. The drug is also associated with an increased risk of thromboembolic events. The beneficial estrogenic activities of raloxifene include a lowering of total and low-density lipoprotein cholesterol levels and an augmentation of bone mineral density. Raloxifene has been labeled by the U.S. Food and Drug Administration for the prevention of osteoporosis. However, its effects on fracture risk and its ability to protect against cardiovascular disease have yet to be determined. Studies are also being conducted to determine its impact on breast and endometrial cancer reduction.

DrugBank Data that Cites this Article

Drugs

Raloxifene

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Raloxifene	Estrogen receptor alpha	Protein	Humans	Yes	Agonist	Details